CryoCor restructures, focuses on heart therapy
CryoCor has decided to lay off 20 of 58 employees as it focuses on gaining approval for a new therapy for irregular heartbeat. Earlier this month the FDA told CryoCor that its trial data did not support an approval for the treatment, which involves freezing tissue that physicians believe causes atrial fibrillation. The therapy was approved in Europe in 2002 and CryoCor executives appear hopeful that more data may change the FDA's mind.
- read this article from the San Diego Union-Tribune
Paid Research Reports
- RNA therapy: the next big thing after monoclonal antibodies?
- Biotech M&A Strategies: Deal assessments, trends and future prospects
- The Dermatology Market Outlook to 2013: Competitive landscape, pipeline analysis and growth opportunities
- Pipeline Insight: Cancer Overview - Breast, Gynecological, Genitourinary - Diverse drugs approaching the market for many tumor t
- Sales Force Effectiveness
